The U.S. FDA approved four new molecular entities (NMEs), bringing the year‑to‑date total to 26 approvals across January and February. The regulator’s early momentum aligns with historical ranges and reflects continued activity across dermatology, endocrinology, and other specialty areas. Agency statistics show a steady approval cadence versus 2025, and the new NMEs include treatments for dermatitis and achondroplasia among other indications. Sponsors and investors are watching therapeutic area mixes, labeling decisions, and post‑approval commitments that will shape commercial launches. The stream of approvals signals that despite broader macro headwinds, regulatory throughput for novel medicines remains robust and will factor into development and partnering strategies throughout 2026.